In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Surprise Winner in MGI Auction

Executive Summary

Everyone knew that MGI Pharma was up for sale, but few expected mid-cap Japanese firm Eisai to emerge victorious. Eisai pushed its offer up to $41-per-share, all cash, even though there was only one other, non-definitive, offer on the table. The $3.3 billion deal nabs Eisai two records: the largest foreign acquisition by any Japanese pharma, and the year's largest specialty pharma purchase.
Advertisement

Related Content

Flush With Cash, Tesaro Advances Rolapitant Toward NDA
Tesaro Scores $101M In A Second Round Of Funding
Best of the Blog: IN VIVO, June 2008
Best of the Blog: IN VIVO, June 2008
Takeda's Global Ambition
Takeda's Global Ambition
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007
Biopharma: Reviewing 2007 to Forecast 2008
Pharmion's Euro Bet Pays Off
Pharmion's Euro Bet Pays Off

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel